Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CNA3103 |
Trade Name | |
Synonyms | |
Drug Descriptions |
CNA3103 are T-lymphocytes engineered to express a chimeric antigenic receptor (CAR) targeting LGR5, which potentially decrease tumor growth (Cancer Res (2022) 82 (12_Supplement): 5574). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CNA3103 | CNA3103 | 0 | 1 |